Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation

This study has been completed.
Sponsor:
Information provided by:
Ramathibodi Hospital
ClinicalTrials.gov Identifier:
NCT01403467
First received: July 25, 2011
Last updated: July 26, 2011
Last verified: December 2010
  Purpose

This current study aimed to demonstrate the effectiveness of the addition of CPAP to the current conventional therapy in terms of airway obstruction improvement in acute asthma patients.


Condition Intervention Phase
Acute Asthma
Device: Continuous positive airway pressure
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation

Resource links provided by NLM:


Further study details as provided by Ramathibodi Hospital:

Primary Outcome Measures:
  • an improvement in PEFR, as % predicted [ Time Frame: 75 mins ] [ Designated as safety issue: No ]

Enrollment: 86
Study Start Date: April 2009
Study Completion Date: January 2011
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NIPPV Device: Continuous positive airway pressure
CPAP 8 cmH2O
Other Name: GoodKnight 420 G; Nellcor Puritan Bennett Inc.

Detailed Description:

Continuous positive airway pressure (CPAP) is widely used in providing ventilator support. However, its role in an acute asthmatic attack is uncertain. The purpose of this study was to compare the efficacy of CPAP when used in addition to conventional therapy with conventional therapy alone in the management of acute asthma exacerbation.

  Eligibility

Ages Eligible for Study:   19 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • aged over 18 years
  • known asthmatic patients visiting ED with acute exacerbation
  • had given their written informed consent.

Exclusion Criteria:

  • smoking history
  • chronic obstructive pulmonary disease
  • required intubation
  • instability of hemodynamic or arrhythmia
  • unable to perform PEFR
  • facial abnormality
  • pulmonary infiltration
  • pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01403467

Locations
Thailand
Ramathibodi Hospital
Bangkok, Thailand, 10400
Sponsors and Collaborators
Ramathibodi Hospital
Investigators
Principal Investigator: Yuda Sutherasan, M.D. Ramathibodi Hospital, Mahidol University
  More Information

No publications provided

Responsible Party: Dr.Yuda Sutherasan, Ramathibodi Hospital
ClinicalTrials.gov Identifier: NCT01403467     History of Changes
Other Study ID Numbers: 02-52-28, MURA2009/1239
Study First Received: July 25, 2011
Last Updated: July 26, 2011
Health Authority: Thailand:Mahidol University

Keywords provided by Ramathibodi Hospital:
Bronchial disease
asthma
continuous positive airway pressure (CPAP)
Bronchoconstriction

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 23, 2014